KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
DUBLIN, Ireland, Feb. 04, 2016 -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February 18, 2016, after the close of the U.S. financial markets. The announcement will be followed by a live audio webcast and conference call at 4:30 PM ET.
The webcast will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.
To access the call via dial-in, please dial (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 33151950. A replay of the call will be available until February 25, 2016 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 33151950.
Separately, Prothena’s presentation time at the upcoming Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 has changed. Prothena will participate in a fireside chat at 9:20 AM ET in New York, NY. The event will be webcast and available on the Company’s website at www.prothena.com under the Investors tab in the Events and Presentations section.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]
